Is There a Generic Version of Humira Available in the US Yet?
No, there is no FDA-approved generic (small-molecule equivalent) for Humira (adalimumab) in the US. Humira is a biologic drug, so equivalents are called biosimilars, which must demonstrate similarity to the reference product. The first Humira biosimilar, Amjevita (adalimumab-atto) from Amgen, gained FDA approval in 2016 but could not launch until January 31, 2023, due to patent settlements and exclusivity protections.[1]
When Did Humira Biosimilars Actually Launch?
Nine Humira biosimilars launched in the US starting January 31, 2023, after AbbVie's 162 patents expired or were settled. These include:
- Amjevita (Amgen)
- Cyltezo (Boehringer Ingelheim)
- Yusimry (Coherus BioSciences)
- Hadlima (Samsung Bioepis)
- Hymiros (Sandoz)
- Idacio (Alvotech/Fresenius Kabi)
- Simlandi (Teva)
- Abrilada (Pfizer)
- And others like Ravsio (Organon).
Interchangeable versions (swappable at pharmacies without prescriber changes) like Cyltezo and Simlandi followed in July 2023. Prices dropped 85-95% below Humira's list price, often under $1,000 per month with rebates.[2][3]
Why Was There Such a Long Wait for Biosimilars?
AbbVie used "patent thickets"—over 100 patents covering the drug, formulation, and delivery devices—to block competition until 2023. This delayed US entry by years compared to Europe (biosimilars since 2018). The FDA's 12-year biologic exclusivity ended in 2023, aligning with patent resolutions.[1]
How Do Humira Biosimilars Compare in Price and Use?
Biosimilars match Humira's efficacy and safety for conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. Upfront costs are lower (e.g., Yusimry at $3,900/month vs. Humira's $6,900+), but insurance coverage varies—many formularies now prefer biosimilars with incentives. Patient switching is common, with no loss in effectiveness reported in studies.[2]
When Do Remaining Humira Patents Expire?
Most patents expired January 31, 2023, but some formulation-specific ones (e.g., high-concentration citrate-free) last until 2025-2030 for certain delivery methods like AbbVie's autoinjectors. This leaves room for litigation; ongoing suits could delay new entrants.[3]
What Are Common Patient Concerns with Switching?
Patients report similar injection-site reactions and efficacy. Access improved post-launch, but shortages occurred early 2023. PBMs (pharmacy benefit managers) often require prior authorization for switches. Real-world data shows 80%+ adherence rates post-switch.[2]
[1]: FDA.gov - Humira Biosimilars Approvals
[2]: DrugPatentWatch.com - Humira Patent Expiry
[3]: USPHS - Biosimilar Launches